Insider · CIK 0001742084

O'Neill Gilmore Neil

Reports to the SEC for 4 companies · CAMBRIDGE, MA

sec.gov

Transactions

Companies

Filings

CIK

0001742084

Forms 4 and 5

Insider transactions

42 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-03	EDITEditas Medicine, Inc.S Sale	Director, CEO	SSale	−5,124 sh	$3.04	−$15.6K	243,189
2026-06-03	EDITEditas Medicine, Inc.S Sale	Director, CEO	SSale	−15.4K sh	$2.70	−$41.5K	248,313
2026-03-12	EDITEditas Medicine, Inc. · Stock Option (right to buy)A Award	Director, CEO	AAward	+1.02M sh	—	—	1,015,200
2026-03-03	EDITEditas Medicine, Inc.S Sale	Director, CEO	SSale	−5,394 sh	$2.02	−$10.9K	263,693
2025-12-03	EDITEditas Medicine, Inc.S Sale	Director, CEO	SSale	−5,603 sh	$2.15	−$12.1K	269,087
2025-09-03	EDITEditas Medicine, Inc.S Sale	Director, CEO	SSale	−5,592 sh	$2.60	−$14.5K	274,690
2025-06-03	EDITEditas Medicine, Inc.S Sale	Director, CEO	SSale	−15.2K sh	$1.72	−$26.2K	280,282
2025-03-08	EDITEditas Medicine, Inc. · Stock Option (right to buy)A Award	Director, CEO	AAward	+828K sh	—	—	828,000
2025-03-08	EDITEditas Medicine, Inc. · Stock Option (right to buy)A Award	Director, CEO	AAward	+175K sh	—	—	175,000
2025-03-04	EDITEditas Medicine, Inc.S Sale	Director, CEO	SSale	−16.6K sh	$1.71	−$28.5K	295,474
2024-12-03	EDITEditas Medicine, Inc.S Sale	Director, CEO	SSale	−1,618 sh	$2.08	−$3,361.233	312,106
2024-09-04	EDITEditas Medicine, Inc.S Sale	Director, CEO	SSale	−1,555 sh	$3.42	−$5,325.409	313,724
2024-06-21	Unity Biotechnology, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+10K sh	—	—	10,000
2024-06-04	EDITEditas Medicine, Inc.S Sale	Director, CEO	SSale	−12.2K sh	$5.50	−$67K	315,279
2024-03-05	EDITEditas Medicine, Inc.S Sale	Director, CEO	SSale	−77.8K sh	$9.42	−$733K	327,470
2024-03-02	EDITEditas Medicine, Inc.A Award	Director, CEO	AAward	+131K sh	—	—	260,869
2024-03-02	EDITEditas Medicine, Inc.A Award	Director, CEO	AAward	+72.2K sh	—	—	333,082
2024-03-02	EDITEditas Medicine, Inc.A Award	Director, CEO	AAward	+72.2K sh	—	—	405,294
2024-03-02	EDITEditas Medicine, Inc. · Stock Option (right to buy)A Award	Director, CEO	AAward	+392K sh	—	—	392,100
2023-06-23	Unity Biotechnology, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+6,000 sh	—	—	6,000
2023-06-05	EDITEditas Medicine, Inc.S Sale	Director, CEO	SSale	−6,486 sh	$9.50	−$61.6K	130,169
2023-03-02	EDITEditas Medicine, Inc.A Award	Director, CEO	AAward	+50K sh	—	—	136,655
2023-03-02	EDITEditas Medicine, Inc. · Stock Option (right to buy)A Award	Director, CEO	AAward	+150K sh	—	—	150,000
2022-06-24	Unity Biotechnology, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+25K sh	—	—	25,000
2022-06-02	EDITEditas Medicine, Inc.A Award	Director, CEO	AAward	+86.7K sh	—	—	86,655
2022-06-02	EDITEditas Medicine, Inc. · Stock Option (right to buy)A Award	Director, CEO	AAward	+950K sh	—	—	950,209
2022-05-26	Aptinyx Inc.Stock Option (Right to Buy)A Award	Director	AAward	+40K sh	—	—	40,000
2021-10-19	Aptinyx Inc.Stock Option (Right to Buy)A Award	Director	AAward	+80K sh	—	—	80,000
2021-06-24	Unity Biotechnology, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+13.4K sh	—	—	13,425
2021-03-03	SRPTSarepta Therapeutics, Inc.A Award	EVP, R&D & CMO	AAward	+15K sh	—	—	29,070
2021-03-03	SRPTSarepta Therapeutics, Inc. · Stock Option (right to buy)A Award	EVP, R&D & CMO	AAward	+60K sh	—	—	60,000
2021-03-03	SRPTSarepta Therapeutics, Inc.A Award	EVP, R&D & CMO	AAward	+15K sh	—	—	28,546
2021-02-28	SRPTSarepta Therapeutics, Inc.F Tax Payment	EVP, R&D & CMO	FTax Payment	−524 sh	$86.97	−$45.6K	13,546
2020-12-10	Unity Biotechnology, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+50K sh	—	—	50,000
2020-02-28	SRPTSarepta Therapeutics, Inc.A Award	EVP, R&D & CMO	AAward	+6,700 sh	—	—	14,070
2020-02-28	SRPTSarepta Therapeutics, Inc. · Stock option (right to buy)A Award	EVP, R&D & CMO	AAward	+37.5K sh	—	—	37,500
2019-05-24	SRPTSarepta Therapeutics, Inc.F Tax Payment	EVP, R&D & CMO	FTax Payment	−4,630 sh	$119.31	−$552K	7,370
2019-05-23	SRPTSarepta Therapeutics, Inc.M Exercise/Conversion	EVP, R&D & CMO	MExercise/Conversion	+12K sh	—	—	12,000
2019-05-23	SRPTSarepta Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	EVP, R&D & CMO	MExercise/Conversion	−12K sh	—	—	0
2019-03-04	SRPTSarepta Therapeutics, Inc. · Stock option (right to buy)A Award	EVP, R&D & CMO	AAward	+55K sh	—	—	55,000
2018-06-07	SRPTSarepta Therapeutics, Inc. · Stock option (right to buy)A Award	EVP, R&D & CMO	AAward	+100K sh	—	—	100,000
2018-06-07	SRPTSarepta Therapeutics, Inc. · Restricted Stock UnitsA Award	EVP, R&D & CMO	AAward	+12K sh	—	—	12,000

Recent filings

Accepted (ET)
Sep 44
O'Neill Gilmore Neil0001742084-26-000003
SEC(opens sec.gov)
Jun 54
O'Neill Gilmore Neil0001650664-26-000056
SEC(opens sec.gov)
Mar 164
O'Neill Gilmore Neil0001650664-26-000023
SEC(opens sec.gov)
Mar 44
O'Neill Gilmore Neil0001650664-26-000009
SEC(opens sec.gov)
Dec 44
O'Neill Gilmore Neil0001650664-25-000162
SEC(opens sec.gov)
Sep 44
O'Neill Gilmore Neil0001650664-25-000141
SEC(opens sec.gov)
Jun 44
O'Neill Gilmore Neil0001650664-25-000089
SEC(opens sec.gov)
Mar 274
O'Neill Gilmore Neil0001650664-25-000037
SEC(opens sec.gov)
Mar 54
O'Neill Gilmore Neil0001650664-25-000026
SEC(opens sec.gov)
Dec 54
O'Neill Gilmore Neil0001650664-24-000126
SEC(opens sec.gov)
Sep 64
O'Neill Gilmore Neil0001650664-24-000103
SEC(opens sec.gov)
Jun 214
O'Neill Gilmore Neil0000950170-24-076285
SEC(opens sec.gov)
Jun 64
O'Neill Gilmore Neil0001650664-24-000076
SEC(opens sec.gov)
Mar 54
O'Neill Gilmore Neil0001650664-24-000015
SEC(opens sec.gov)
Jun 264
O'Neill Gilmore Neil0000899243-23-016504
SEC(opens sec.gov)

Companies

Address

C/O EDITAS MEDICINE, INC. 11 HURLEY ST.

CAMBRIDGE, MA, 02141